Nephros vs Vivos Therapeutics
Nephros and Vivos Therapeutics are similar in size: $18.8m and $17.4m of revenue in their latest fiscal years. Nephros grew faster (32.7% against 16.0%). Nephros kept more of each dollar of sales as profit: a net margin of 6.4% against -121.4%.
| Latest fiscal year | NephrosNEPH, 2025 | Vivos TherapeuticsVVOS, 2025 |
|---|---|---|
| Revenue | $18.8m | $17.4m |
| Revenue growth | 32.7% | 16.0% |
| Net income | $1.2m | −$21.2m |
| Operating margin | 6.1% | -114.1% |
| Net margin | 6.4% | -121.4% |
| Return on equity | 12.7% | — |
| Free cash flow | $1.6m | −$17.6m |
| Cash | $5.4m | $2.0m |
| Total debt | $0 | $19.3m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 268 |
| Market value | $35.1m | $1.6m |
| Price vs our value range | — | — |
| Moat score | 31 (Weak) | 30 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 0 sales |